19 May 2010 07:01
FOR IMMEDIATE RELEASE 19 May 2010
IMMUPHARMA RECEIVES APPROVAL FOR
INITIATION OF PHASE I/IIA STUDIES IN CANCER
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that it received an Investigational New Drug (IND) approval from AFSSAPS, Agence Francaise de Securite Sanitaire des Produits de Sante, for a Phase I/IIa study in patients of IPP-204106, its anti-cancer compound with a novel and promising mechanism of action. The first patients are expected to be dosed within the next few weeks.
Dr Robert Zimmer, President and Chief Scientific Officer, said: "We are delighted with the approval of our IND application, and are excited to begin Phase I in patients for IPP-204106 in the next few weeks. Importantly, our strong financial position means we are well-placed to take the development programme forward."
For further information please contact:
ImmuPharma PLC
Robert Zimmer, President & Chief Scientific Officer +33 3 8932 7650
Richard Warr, Chairman +44 20 7152 4080 Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Buchanan Communications + 44 20 7466 5000
Lisa Baderoon Catherine Breen
George Prassas
Panmure Gordon & Co +44 151 243 0963
Andrew Burnett
Rakesh Sharma
Execution Noble & Co
James Bromhead +44 20 7456 9191
Immupharma (IMM)